Recombinant Mouse IGF-II/IGF2 (Catalog # 792-MG) stimulates proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse IGF-II/IGF2 ...read more
IGF-II/IGF2 was detected in immersion fixed frozen sections of mouse embryo (E13-17) using Mouse IGF-II/IGF2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF792) at 15 µg/mL overnight at 4 °C. Tissue was ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for IGF-II/IGF2 Antibody [Unconjugated]
chromosome 11 open reading frame 43
insulin-like growth factor 2 (somatomedin A)
insulin-like growth factor II
insulin-like growth factor type 2
IGF-II (Insulin-like growth factor II; also multiplication-stimulating polypeptide/MSP and somatomedin-A) is a secreted 8 kDa polypeptide that belongs to the insulin family of peptide growth factors (1‑3). It is part of a complex system of growth and metabolic-regulating proteins that is particularly important during development. It has been associated with nervous system proliferation and differentiation, myelination, adrenal cortical proliferation, and skeletal growth and differentiation (4). In humans, IGF-II is primarily synthesized by the liver and circulates at high levels in both fetus and adult. In rodents, however, IGF-II levels drop after the perinatal period, an effect attributed to the lack of a key gene promoter (2, 5). This may indicate that postnatally, IGF-II has either a limited or local effect only in rodents. For example, evidence suggests IGF-II may be the intermediary for SHH induction of VEGF attendant with local neovascularization (6). Rodent cells known to express IGF-II include astrocytes (7), hepatocytes (8), osteoblasts (9), embryonic striated muscle cells (10, 11), plus Kupffer cells and Ito cells (12). Mouse IGF-II is synthesized as a 180 amino acid (aa) preproprecursor (13). It contains a 24 aa signal sequence, a 67 aa mature region, and an 89 aa C-terminal prodomain that is alternatively referred to as the E-peptide. Mature IGF-II is 91% and 97% aa identical to human and rat IGF-II, respectively. Proper processing of IGF-II requires the chaperone activity of GRP94 (14). This generates an 8 kDa mature form, an 18 kDa, 156 aa proform, and a potential 11 kDa, 88 aa “Big” form (aa 25-112). This 11 kDa ”Big” form would be equivalent to human 15-16 kDa IGF-II, with the 5 kDa difference attributable to the presence of O-linked glycosylation (15). There is an additional 34 aa proteolytic fragment that is termed preptin and contains aa 93-126 of the preproprecursor. This is distinct from IGF-II, is secreted by pancreatic B cells, and facilitates insulin secretion (16, 17). IGF-II has multiple binding partners. It binds to IGF-I R, the Insulin receptor (IR)-type A and IGF-IR:IR-A hybrids, the type II IGF receptor (IGF-II R), and IGF binding proteins 1-6 (18, 19). The first three receptors initiate downstream signaling events, the IGF-II R sequesters local IGF‑II, and the six IGFBPs regulate IGF-II activity in various tissues.
LeRoith, D. and C.T. Roberts Jr. (2003) Cancer Lett. 195:127.
Werner, H. and D. LeRoith (2000) Cell. Mol. Life Sci. 57:932.
Pavelic, J. et al. (2007) Indian J. Med. Res. 125:511.
Varela-Nieto, I. et al. (2007) Curr. Pharm. Des. 13:687.
Rotwein, P. and L.J. Hall (1990) DNA Cell Biol. 10:725.
Chao, W. and P.A. D-Amore (2008) Cytokine Growth Factor Rev. 19:111.
Rotwein, P. et al. (1988) Proc. Natl. Acad. Sci. USA 85:265.
Goya, L. et al. (1999) J. Biol. Chem. 274:24633.
McCarthy, T.L. et al. (1992) Endocrinology 130:1303.
Zindy, F. et al. (1992) J. Hepatol. 14:30.
Holthuizen, P.E. et al. (1993) Regul. Pept. 48:77.
Merrick, D. et al. (2007) BMC Dev. Biol. 7:65.
Stempien, M.M. et al. (1986) DNA 5:357.
Ostrovsky, O. et al. (2009) Mol. Biol. Cell 20:1855.
Daughaday, W.H. et al. (1993) Proc. Natl. Acad. Sci. USA 90:5823.
Buchanan, C.M. et al. (2001) Biochem. J. 360:431.
Cornish, J. et al. (2007) Am. J. Physiol. Endocrinol. Metab. 292:E117.
Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.
Belfiore, A. (2007) Curr. Pharm. Des. 13:671.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our IGF-II/IGF2 Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.